AU Patent
AU2019328530B2 — Compositions of CXCR4 inhibitors and methods of preparation and use
Assigned to X4 Pharmaceuticals Inc · Expires 2025-02-27 · 1y expired
What this patent protects
The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
USPTO Abstract
The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
Drugs covered by this patent
- Xolremdi (MAVORIXAFOR) · X4 Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.